Last reviewed · How we verify
ANTHRALIN
Anthralin, a topical small molecule, is used for the treatment of psoriasis. It works by inducing keratinocyte differentiation and inhibiting DNA synthesis. Anthralin is approved for psoriasis and has been marketed for decades. It is a generic drug with no current patent protection, making it widely accessible. Despite its long history, it remains a viable option for psoriasis management due to its unique mechanism of action and low cost.
At a glance
| Generic name | ANTHRALIN |
|---|---|
| Also known as | dithranol |
| Drug class | Topical antipsoriatic |
| Target | Keratinocyte differentiation and DNA synthesis |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Psoriasis — any
Pipeline indications
- Psoriasis Vulgaris — Phase 4
Common side effects
- Transient primary irritation
- Staining of hair or skin
- Temporary discoloration of hair and skin
- Contact allergic reactions
Key clinical trials
- PGE2/IL-22 Pathway in Various Forms of Eczema
- Evaluation of Vitamin D Levels in Psoriasis Patients
- Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis (PHASE4)
- Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis (PHASE4)
- Study on the Therapeutic Mechanisms of Dithranol Treatment in Patients With Chronic Plaque Psoriasis
- Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |